Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Valorum will advance the commercialization and distribution of Armlupeg in the United States
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
Growing patent filings and tier-2 innovators reflect expanding national research base
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Subscribe To Our Newsletter & Stay Updated